echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > After being removed from the medical insurance catalogue by "key monitoring", the auxiliary drugs should wear "tight hoop" on their heads

    After being removed from the medical insurance catalogue by "key monitoring", the auxiliary drugs should wear "tight hoop" on their heads

    • Last Update: 2019-12-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    A few days ago, the State Food and Drug Administration issued the announcement on the revision of the manual of Cattle Encephalon Glycoside and Ignotin Injection and the announcement on the revision of the manual of compound osteopeptide injection, requiring the two drugs to add [warning words], revise [contraindications] and [precautions] in the manual This is equivalent to "wearing a new hoop on the head" for these two supplementary drugs In fact, since this year, the publication of the "key monitoring catalogue" and the adjustment of the "national medical insurance catalogue" are all intended to "encircle and suppress" auxiliary drugs This revision of the manual makes these two auxiliary drugs "worse", and it is believed that other auxiliary drugs will suffer "the same treatment" in the future So, should adjuvant drugs be completely banned? Can related enterprises find a new way out? It is understood that the national food and drug administration requires to revise the manual of brain glycoside and carnosine injection The domestic manufacturers are mainly Jilin Sihuan pharmaceutical and Jilin Zhenao pharmaceutical The manufacturers of compound bone peptide injection mainly include Nanjing Xinbai Pharmaceutical Co., Ltd., Heilongjiang Jiangshi Pharmaceutical Co., Ltd., Hebei zhitongwu Pharmaceutical Co., Ltd and Changzhou Fangyuan Pharmaceutical Co., Ltd In 2018, the terminal sales of these two varieties in China's public medical institutions were 3.3 billion yuan and 800 million yuan respectively Tu Honggang, chairman of the board of directors of the medical software, said that the revision of the manual would certainly have a certain impact on the sales of the two varieties, especially the revision requirements of the manual of compound osteopeptide injection, which should be noted: Children's prohibition, pregnant women and lactating women's prohibition, severe liver and kidney dysfunction prohibition, elderly people's use without reliable reference materials, medical staff should weigh the advantages and disadvantages, use as appropriate, etc , which will greatly limit the population of drug users Doctors will be relatively cautious or use other products to replace other people In addition, this time, the drug administration separately requested to revise the instruction manual for the "monosialotetrahexosylganglioside" contained in the injection of cerebrosine and carnosine, which is undoubtedly to further strengthen the control of key monitoring drugs Therefore, the market of these two varieties will further shrink Shi lichen, a special observer of this newspaper and founder of Dingchen medical consulting, also analyzed that since this year, after many traditional Chinese medicine injections were required to revise the instruction manual, the sales volume has declined significantly This time, the auxiliary drugs were required to add [warning words] in the instruction manual, and after the [taboos] and [precautions] were revised, the scope of use has been significantly reduced, and many doctors will be cautious in prescribing Not only do we need to revise the instructions, this year's "key monitoring directory" and "national health insurance directory" were adjusted, aiming at auxiliary drugs, and some hospitals even simply stopped using them So, is adjuvant really at the end of the road? Is it really worth denying? In fact, adjuvant drugs should really be called "adjuvant drugs", so that patients can get better results and recover faster in the process of treatment, he said In clinic, some therapeutic drugs have strong side effects, but when combined with auxiliary drugs, they can obviously reduce side effects, or even have no side effects Therefore, adjuvants cannot be totally denied Now the reason why auxiliary drugs are mainly monitored is also related to a very important problem: the top ten drugs in the international drug market are basically therapeutic drugs, but most of them are occupied by auxiliary drugs in China This is the focus of the problem Medical insurance funds are hard to bear, so it's easy to understand that they are monitored Now a series of measures issued by the regulatory authorities are to promote the rational use of drugs, change the prescribing habits of Chinese doctors, and then adjust the research and development structure and clinical application structure of Chinese drugs Tu added that under the new centralized mining mode, the auxiliary drugs with low price and clinical necessity may usher in a new wave of opportunities to meet the clinical needs Although complementary drugs are still valuable in clinical use, however, the negative impact of policies on them is obvious, which is also reflected in the capital market This year's mid-term report and the third quarter report show that the performance of listed companies with auxiliary drugs as their main business has declined significantly, and the share price has declined Sihuan medicine is a typical example According to Tu Honggang, in the national version of "key monitoring catalogue", there are 7 products of Sihuan pharmaceutical, which account for 78.9% of the company's total sales in the first half of 2019 According to its mid-2019 report, the net profit in the first half of the year was - 1964.097 million yuan, a year-on-year decrease of 349.81% In this regard, Tu Honggang said that since this year, a series of policies aimed at auxiliary drugs have seriously injured the pharmaceutical companies that originally sold large-scale auxiliary drugs, which to some extent affected the confidence of some investors in the pharmaceutical sector However, he also stressed that the large-scale innovative drug head enterprises will receive the bonus of "cage lifting and bird changing" In the context of volume purchasing and consistency evaluation, more market increments will turn to therapeutic products and innovative drugs, so innovative drugs and high-end generic drugs will usher in great opportunities! Mr Shi also said that the impact of the policy on listed companies of auxiliary drugs is certain, but it will not fundamentally affect investors' confidence in the pharmaceutical sector Because on the one hand, the state's support for new drug research and development is growing, and the application, approval, etc are speeding up; on the other hand, the medical insurance catalog negotiation also has great support for new drugs In addition, the focus of capital investment in the pharmaceutical industry is not on adjuvant drugs, but on therapeutic drugs Obviously, driven by the policy, both the market and the capital are "abandoning" the auxiliary drugs Should the relevant enterprises give up the products completely? If we can't give up for a while, how can we find the survival value for our products? First of all, there is almost no possibility of giving up completely, because the main products of many enterprises are auxiliary drugs Once they give up, they will be closed As mentioned earlier, auxiliary drugs are not useless Pharmaceutical companies must fully tap their clinical value, such as promoting tissue metabolism, nutrition and nerves, etc On the one hand, enterprises should think about how to go in the future Auxiliary drugs must not be used as the main marketing products, so they must optimize the product structure and transfer to therapeutic products On the other hand, in terms of specific operation, there are several directions to try The first is to "take off the hat", excavate the therapeutic effect of the medicine as soon as possible, take off the hat of "auxiliary", or form a new treatment scheme with the therapeutic medicine; the second is to "go to the grass-roots level", from the large-scale second, third and third class hospitals to the grass-roots medical institutions; the third is to "transfer outside the hospital", in this process, the first step is to solve the doctor's prescription problem Tu Honggang also said that auxiliary drug companies must transform, which is certainly a painful and long process At present, the first task is to reduce the cost, reduce the drug price, carry out low-cost marketing on the premise of ensuring the safety and quality of drugs, so as to play an advantage in the medical insurance control fee and fierce market competition and keep a place in the market Some auxiliary drugs can be used in combination with existing drugs, and some injection products can also be changed into oral dosage forms As a matter of fact, some enterprises of auxiliary drugs have been preparing for the future and have created new therapeutic drugs in addition to auxiliary drugs Now, the transformation is much easier For example, one of the manufacturers of ganglioside, Theron pharmaceutical recently launched peri operative pain new drug parecoxib sodium for injection (trade name "sesulin") For these enterprises to prepare for the future, Mr Shi said that many far-sighted pharmaceutical enterprises have observed the wind direction of the industry in the past few years and opened the road of transformation, including auxiliary drug enterprises and traditional Chinese medicine injection enterprises It should not be a big problem for Cylon pharmaceutical and the new product of the enterprise to quickly open up the market and help the enterprise transform successfully On the one hand, the new product is connected with the application department of ganglioside, and the original market resources and clinical resources can be directly used, so that the market can be opened quickly; on the other hand, the state has a great support for the clinical use of this new drug, and capital will also favor it With the support of market, policy and capital, we believe that Cylon pharmaceutical industry will succeed in transformation But Tu Honggang expressed his concern He said that the new products need to rebuild the team, and the "high pricing and high cost" model of the original products is not sustainable Moreover, how to establish a pipeline for a single product to share the marketing cost is a real problem that needs to be solved Therefore, he holds a cautious view on the transformation of auxiliary drug enterprises Tu Honggang also suggested that when there is capital for the transformation of auxiliary drug enterprises, innovative drug research and development, or investment and acquisition of biopharmaceutical projects can be done; when there are sales channels, product upgrading can be done, or multiple generic drug projects can be done at the same time according to the original advantage pipeline In terms of marketing, low-cost marketing and digital marketing, as well as patient education and management, and cooperation with the upstream and downstream of the industrial chain The era of "eating all the dishes in one move" relying on marketing expenses has passed!
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.